Taysha Gene Therapies, Inc. (TSHA)
4.445
+0.06
(+1.25%)
USD |
NASDAQ |
Oct 07, 16:00
4.445
0.00 (0.00%)
After-Hours: 20:00
Taysha Gene Therapies Gross Profit Margin (Quarterly)
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2025 | 94.55% |
| September 30, 2025 | |
| June 30, 2025 | 86.05% |
| March 31, 2025 | 87.71% |
| December 31, 2024 | 84.97% |
| September 30, 2024 | 83.22% |
| June 30, 2024 | 73.02% |
| Date | Value |
|---|---|
| March 31, 2024 | 90.47% |
| December 31, 2023 | 89.84% |
| September 30, 2023 | 93.03% |
| June 30, 2023 | 70.65% |
| March 31, 2023 | 86.59% |
| December 31, 2022 | 32.89% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Altimmune, Inc. | -- |
| Protalix Biotherapeutics, Inc. | 60.99% |
| Humacyte, Inc. | -423.2% |
| Agenus, Inc. | 98.50% |
| Amgen, Inc. | 72.08% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -56.94% |
| Return on Assets | -39.29% |
| Return on Invested Capital | -45.63% |
| Return on Net Operating Assets | -869.6% |